Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Sonoma Q1 revenue up; EBITDA turns positive as US demand surges

Aug 6, 2026, 8:51 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong quarterly growth, EBITDA turn positive, and a healthy cash balance reduce downside risk and may attract investors; catalysts include FDA clearances and new/distributor partnerships. However, execution risk and sustainability of quarterly timing in Asia/RoW revenue warrant caution.

AI summary

What happened, with direct paths to the underlying reporting

Sonoma Pharmaceuticals reported a Q1 inflection point with $6.4 million in revenue, a $2.4 million year-over-year increase. U.S. sales rose 141% to $1.4 million, while Europe grew 34% to $0.5 million, supporting margins of 40% and a positive EBITDA of $0.1 million. With $5.3 million in cash and ongoing FDA clearances and distribution partnerships, the company signals profitable growth potential ahead.

Q1 revenue $6.4M, up $2.4M YoY.
US sales +141% to $1.4M driven by OTC demand and distributors.
Gross profit $2.6M; 40% margin; EBITDA positive $0.1M.
Cash $5.3M as of 6/30/2026; FDA clearances and distribution expansion cited.
Shares up 9.73% premarket; CEO cites growth pipeline and profitability.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.